|本期目录/Table of Contents|

常规化疗联合替吉奥对乳腺肿瘤患者淋巴结转移的影响

《现代肿瘤医学》[ISSN:1672-4992/CN:61-1415/R]

期数:
2019年20期
页码:
3633-3636
栏目:
论着(胸部肿瘤)
出版日期:
2019-09-08

文章信息/Info

Title:
Influence study of conventional chemotherapy plus Tegafur,Gimeracil and Oteracil Potassium Capsules in the lymphatic metastasis for breast neoplasm patients
作者:
王 岩1;?汪亮亮2;?刘 韬3;?陈永进3;?赵庚雷3;?王 婷4
1.九江学院附属医院乳腺外科;2.病理科,江西 九江 322000;3.成都中医药大学附属医院乳腺外科,四川 成都 610072;4.四川省肿瘤医院肿瘤科,四川 成都 610072
Author(s):
Wang Yan1;?Wang Liangliang2;?Liu Tao3;?Chen Yongjin3;?Zhao Genglei3;?Wang Ting4
1.Breast Surgery Department;2.Pathology Department,Jiujiang University Hospital,Jiangxi Jiujiang 322000,China;3.Breast Surgery Department,Affiliated Hospital of Chengdu University of TCM,Sichuan Chengdu 610072,China;4.Oncology Department,Sichuan Tumor Hospital,Sichuan Chengdu 610072,China.
关键词:
化疗;?替吉奥;?乳腺肿瘤;?淋巴结转移
Keywords:
chemotherapy;?Tegafur;?Gimeracil and Oteracil Potassium Capsules;?breast neoplasm;?lymphatic metastasis
分类号:
R737.9
DOI:
10.3969/j.issn.1672-4992.2019.20.019
文献标识码:
A
qq自动领红包软件:
目的:研究常规化疗联合替吉奥对乳腺肿瘤患者淋巴结转移的影响。方法:临床纳入2016年5月至2017年5月期间我院收治的84例乳腺肿瘤患者进行研究,按随机数字表法分为两组各42例。其中42例患者采用常规化疗治疗作为对照组;另42例患者在常规化疗的基础上给予替吉奥治疗作为观察组。观察患者淋巴转移、肿瘤标志物水平和不良反应情况。结果:观察组淋巴结转移率为7.14%,明显低于对照组的28.57%,P<0.05。治疗前两组患者CEA、CA15-3以及CA125水平对比无差异,P>0.05;治疗后观察组CEA、CA15-3以及CA125水平明显低于对照组,P<0.05。观察组不良反应发生率为21.43%,对照组为16.67%,两组不良反应发生率对比无差异,P>0.05。结论:替吉奥可有效抑制乳腺肿瘤的淋巴结转移,促进化疗效果,且安全性较高,值得临床应用及推广。
Abstract:
Objective:To study the influence of conventional chemotherapy plus Tegafur,Gimeracil and Oteracil Potassium Capsules on the lymphatic metastasis for breast neoplasm patients.Methods:84 breast neoplasm patients,between May 2016 and May 2017,admitted to our hospital were enrolled into the study.Random number table was used for 42 cases in each group.The control group was treated with conventional chemotherapy.The observation group received with Tegafur,Gimeracil and Oteracil Potassium Capsules regimen.The lymphatic metastasis rate,tumor markers and adverse reactions were evaluated.Results:The lymphatic metastasis rate in the observation group (7.14%) was significantly lower than that in control group (28.57%)(P<0.05).Before treatment,the values of CEA (carcino-embryonic antigen),CA15-3 (carbohydrate antigen 15-3) and CA125 (cancer antigen 125) for two groups were not significantly different (P>0.05).After treatment,the values of CEA,CA15-3 and CA125 in the observation group were significantly lower than control group (P<0.05).The adverse event rate in the observation group (21.43%) and control group (16.67%) was not significantly different (P>0.05).Conclusion:The Tegafur,Gimeracil and Oteracil Potassium Capsules can efficiently inhibit the lymphatic metastasis,and increase the chemotherapy efficacy and clinical safety,which is worthy of clinical application and promotion.

参考文献/References

[1]LI Jien,WANG Xudong,JIANG Zaipeng,et al.Effect observation of tegafur-gimeracil-oteracil potassium capsules plus three-dimensional conformal radiotherapy in triple negative breast cancer [J].Shandong Medical Journal,2016,56(18):45-47.[李继恩,王旭东,姜在鹏,等.替吉奥口服联合三维适形放疗治疗三阴性乳腺癌效果观察[J].山东医药,2016,56(18):45-47.]
[2] ZHANG Zhonglin.Influence of tegafur-gimeracil-oteracil potassium in lymphatic metastasis conditions for breast cancer patients [J].Chinese Journal of Current Advances in General Surgery,2016,19(11):918-920.[张忠林.替吉奥对乳腺肿瘤患者淋巴结转移的影响[J].中国现代普通外科进展,2016,19(11):918-920.]
[3] ZHOU Jianlin,ZHANG Wufang,YANG Wusen,et al.Influence of tegafur-gimeracil-oteracil potassium in serum tk1,Vegf,Igf-1,tumor markers and estrogen contents for advanced breast cancer patients [J].Chinese Journal of Biochemical Pharmaceutics,2015,35(8):69-71.[周建林,张武坊,杨武森,等.替吉奥对晚期乳腺癌患者血清TK1、VEGF、IGF-1和肿瘤标志物、雌激素水平的影响[J].中国生化药物杂志,2015,35(8):69-71.]
[4] WANG Shaomin,YE Meng,NI Shumin,et al.Effect analysis of tegafur-gimeracil-oteracil potassium in metastatic breast cancer with Capecitabine drug resistance [J].Chinese General Practice,2017,20(20):2469-2473.[王少敏,叶孟,倪曙民,等.替吉奥治疗卡培他滨耐药转移性乳腺癌的疗效分析[J].中国全科医学,2017,20(20):2469-2473.]
[5] DING Rongmei,WANG Ping,MA Lijun,et al.Effect and safety evaluation of tegafur-gimeracil-oteracil potassium in recurrent metastatic breast cancer patients [J].Hebei Medical Journal,2016,38(5):687-690.[丁荣楣,王平,马丽君,等.替吉奥联合放疗对复发转移性乳腺癌的疗效及安全性评价[J].河北医药,2016,38(5):687-690.]
[6] LI Ying,JIANG Da,WU Yuanyuan,et al.Multi-center clinical study of tegafur-gimeracil-oteracil potassium plus Capecitabine in the treatment of progressive breast cancer [J].Chin J Oncol,2017,39(8):607-612.[李颖,姜达,吴圆圆,等.替吉奥和卡培他滨治疗进展期乳腺癌的多中心临床研究[J].中华肿瘤杂志,2017,39(8):607-612.]
[7] Ishizuna K,Ninomiya J,Ogawa T,et al.Effectiveness and safety of tegafur-gimeracil-oteracil potassium (TS-1) for metastatic breast cancer:a single-center retrospective study[J].Gan To Kagaku Ryoho,2014,41(13):2577-2582.
[8] JIAO Yang,NING Jie,WANG Fang,et al.Effect and safety comparison of tegafur-gimeracil-oteracil potassiumin in the treatment of advanced breast cancer [J].Chinese Journal of Cancer Prevention and Treatment,2016,23(7):452-456.[焦洋,宁洁,王芳,等.晚期乳腺癌替吉奥与卡培他滨治疗疗效及安全性对比研究[J].中华肿瘤防治杂志,2016,23(7):452-456.]
[9] FAN Jingjing,LI Hui.Clinical observation of combined chemotherapy with Gemcitabine and tegafur-gimeracil-oteracil potassium during the radical operation of pancreatic cancer [J].Chinese Journal of Biochemical Pharmaceutics,2017,37(10):292-293.[范菁菁,李慧.吉西他滨联合替吉奥化疗与心理干预对胰腺癌根治术患者的临床观察[J].中国生化药物杂志,2017,37(10):292-293.]
[10] QU Shuxian,ZHENG Zhendong,LIU Zhaozhe,et al.Efficacy and safety of third-line therapy with Gemcitabine and tegafur-gimeracil-oteracil potassium capsules in the treatment of metastatic triple negative breast cancer [J].Chinese Journal of Endocrine Surgery,2015,9(1):41-44.[屈淑贤,郑振东,刘兆喆,等.吉西他滨联合替吉奥胶囊三线治疗转移性三阴乳腺癌的疗效和安全性[J].中华内分泌外科杂志,2015,9(1):41-44.]
[11] REN Ruiping,YANG Hui,YUAN Zuguo,et al.Clinical research of Oxaliplatin injection plus tegafur-gimeracil-oteracil potassium capsules in advanced triple negative breast cancer patients [J].The Chinese Journal of Clinical Pharmacology,2017,33(24):2566-2568.[任瑞平,杨辉,袁祖国,等.奥利沙铂注射剂联合替吉奥胶囊治疗晚期三阴乳腺癌的临床研究[J].中国临床药理学杂志,2017,33(24):2566-2568.]
[12] LIU Jun,XIAO Yang,GUO Jianxiong,et al.Compare the effect and adverse reactions of Oxaliplatin plus tegafur-gimeracil-oteracil potassium and Cisplatin in advanced triple negative breast cancer patients [J].Cancer Research on Prevention and Treatment,2016,43(1):72-77.[刘君,肖扬,郭建雄,等.奥沙利铂联合替吉奥和吉西他滨联合顺铂治疗晚期三阴性乳腺癌的疗效和不良反应比较[J].肿瘤防治研究,2016,43(1):72-77.]
[13] Yamamoto Y,Nishimura R,Tanigawa T,et al.Efficacy and safety of TS-1 monotherapy for advanced/metastatic breast cancer - an observational study by the Kumamoto Breast Cancer Cooperative Group(KBCCG)[J].Gan To Kagaku Ryoho,2014,41(10):1221-1225.
[14] LIU Jun,XIAO Yang,MA Yihui,et al.Clinical observation of Oxaliplatin plus tegafur-gimeracil-oteracil potassium in refractory advanced triple negative breast cancer patients [J].Journal of International Oncology,2016,43(5):330-334.[刘君,肖扬,马益慧,等.奥沙利铂联合替吉奥治疗难治性晚期乳腺癌临床观察[J].国际肿瘤学杂志,2016,43(5):330-334.]
[15] BAI Yun,TAO Yang,WANG Chongjie,et al.Compare the efficacy and adverse reactions of Oxaliplatin plus tegafur-gimeracil-oteracil potassium or Gemcitabine plus Cisplatin in advanced triple negative breast cancer patients [J].Chinese Journal of Biochemical Pharmaceutics,2017,37(4):293-295.[白云,陶阳,王崇杰,等.应用奥沙利铂联合替吉奥以及吉西他滨联合顺铂方案对晚期三阴性乳腺癌的疗效与不良反应比较[J].中国生化药物杂志,2017,37(4):293-295.]

备注/Memo

备注/Memo:
四川省卫计委普及应用科研课题项目(编号:17PJ566)
更新日期/Last Update: 1900-01-01